MUMBAI : Shares of Cadila Healthcare climbed as much as 6.49% on Monday after the company received US drug regulator's final approval for Potassium Chloride extended-release tablets.At 01:50 pm, Cadila Healthcare was trading at ₹418.35 up 6.13%, while the benchmark Sensex advanced 0.26% to 39,081.83 points.Zydus Cadila has received final approval from the US Food and Drug Administration (US FDA) to market Potassium Chloride extended-release tablets in the strengths of 750 mg and 1500 mg, it said in a regulatory filing.The medication is a mineral supplement used to treat or prevent low amounts of potassium in the blood and will be manufactured at the group's formulation manufacturing facility at the SEZ, Ahmedabad.Cadila is in talks with the.